2008
- 09 December 2008
Ambit Biosciences Presents Data on its Targeted Cancer Therapeutic AC220 for Acute Myeloid Leukemia - 13 November 2008
Ambrx - Clinical Data Shows Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated - 12 August 2008
Serentis announces new investment to advance dermatology pipeline - 16 June 2008
Cutting-edge cancer services launched under new partnership between CancerPartners UK and Spire Healthcare - 31 March 2008
Serentis appoints Gunnar Staaf as Commerical Director - 26 February 2008
Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development